CEO Sandesh Seth was paid $1,173,200 in fiscal year 2024, ↓ down 75.1% from fiscal year 2023 (SEC filing 0001213900-25-106706 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$1,173,200 ↓ Sandesh Seth total, FY2024 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | 74.41% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
ATNM's next annual pay disclosure, estimated November 5, 2026.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Sandesh Seth | $733,200 | $440,000 | $0 | $0 | $0 | $0 | $0 | $1,173,200 |
| Chairman and Chief Executive Officer (3) | ||||||||
| Steve O’Loughlin | 436,800 | 145,000 | 0 | 0 | 0 | 0 | 0 | 581,800 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Sandesh Seth | $1,173,200 | $4,705,000 | — | ↓ −3,531,800 |
| Steve O’Loughlin | 581,800 | 1,490,000 | — | ↓ −908,200 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Actinium Pharmaceuticals's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ATNM reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses ATNM in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ATNM in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Sandesh Seth | RSU | 300,000 | — | $378,000 |
| Sandesh Seth | Option | 68,241 | 6.07 | — |
| Sandesh Seth | Option | 347,494 | 4.96 | — |
| Sandesh Seth | Option | 748,119 | 5 | — |
The Company's compensation program is designed to align executive compensation with the Company's performance and long-term interests, with base salaries set to be competitively aligned to a range between the 25th and 75th percentile of relevant market data for similarly situated publicly traded companies. The Board has determined that the compensation programs do not encourage excessive risk and instead encourage behaviors that support sustainable value creation.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-10-15 | 4,481,875 | 1,541,460 | 243,885 | 74.41% | Passed |
| 2022 | 2022-12-30 | 9,832,125 | 2,559,430 | 387,341 | 79.35% | Passed |
| 2018 | 2018-12-18 | — | — | — | — | — |
| 2017 | 2017-12-20 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-10-15 | 74.41%a |
| 2022 | 2022-12-30 | 79.35%b |
| 2018 | 2018-12-18 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| June S. AlmenoffIndependent · Nominating and Corporate Governance · Newly elected | $8,333 | $0 | $65,611 | — | $0 | $73,944 |
| Ajit S. ShettyIndependent · Audit · Compensation · Nominating and Corporate Governance (Chair) | 72,500 | 0 | 0 | — | 0 | 72,500 |
| Richard I. SteinhartIndependent · Audit (Chair) · Nominating and Corporate Governance | 70,000 | 0 | 0 | — | 0 | 70,000 |
| David NicholsonIndependent · Lead Independent Director · Compensation | 70,000 | 0 | 0 | — | 0 | 70,000 |
| Jeffrey W. ChellIndependent · Audit · Compensation | 62,500 | 0 | 0 | — | 0 | 62,500 |
| Sandesh SethEmployee director · Board Chair | — | — | — | — | — | 0 |
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $283,333 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $283,333 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Actinium Pharmaceuticals | 2024 | Sandesh Seth | $733,200 | $0 | $0 | $0 | $1,173,200 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Sandesh Seth | DEF 14A | 2025-11-05 | 0001213900-25-106706 | Section “Executive Compensation”. As printed: 1,173,200. Filing ↗machine: r1 · c17 · span 505836–505845 |
| 2 | Section 01, Steve O’Loughlin | DEF 14A | 2025-11-05 | 0001213900-25-106706 | Section “Executive Compensation”. As printed: 581,800. Filing ↗machine: r4 · c17 · span 536965–536972 |
| 3 | Section 08, June S. Almenoff | DEF 14A | 2025-11-05 | 0001213900-25-106706 | Section “Director Compensation”. As printed: 73,944. Filing ↗machine: span 294400–294780 |
| 4 | Section 08, Ajit S. Shetty | DEF 14A | 2025-11-05 | 0001213900-25-106706 | Section “Director Compensation”. As printed: 72,500. Filing ↗machine: span 315135–315515 |
| 5 | Section 08, Richard I. Steinhart | DEF 14A | 2025-11-05 | 0001213900-25-106706 | Section “Director Compensation”. As printed: 70,000. Filing ↗machine: span 324233–324613 |
| 6 | Section 08, David Nicholson | DEF 14A | 2025-11-05 | 0001213900-25-106706 | Section “Director Compensation”. As printed: 70,000. Filing ↗machine: span 306055–306435 |
| 7 | Section 08, Jeffrey W. Chell | DEF 14A | 2025-11-05 | 0001213900-25-106706 | Section “Director Compensation”. As printed: 62,500. Filing ↗machine: span 296959–297339 |
| 8 | Section 08, Sandesh Seth | DEF 14A | 2025-11-05 | 0001213900-25-106706 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 9 | Section 06, 2025 vote | Form 8-K | 2025-11-26 | 0001213900-25-115586 | Item 5.07 · say-on-pay result. As reported: 74.41% (votes for as printed: 4,481,875). Filing ↗ |
| 10 | Section 06, 2022 vote | Form 8-K | 2022-12-30 | 0001213900-22-084094 | Item 5.07 · say-on-pay result. As reported: 79.35% (votes for as printed: 9,832,125). Filing ↗ |
| 11 | Section 06, 2018 vote | Form 8-K | 2018-12-21 | 0001213900-18-017740 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 12 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 13 | Section 09b board cost (computed) | Computed | — | — | Cash 283,333 + equity 0 + all other 0 = 283,333, summed across the director compensation table rows.machine: formula: Σ = 283,333 |
| 14 | Actinium Pharmaceuticals (subject), Section 10b CEO total | DEF 14A | 2025-11-05 | 0001213900-25-106706 | CEO total compensation as printed in Actinium Pharmaceuticals's own proxy. As printed: 1,173,200. Filing ↗machine: r1 · c17 · span 505836–505845 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.